Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Current Assets (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Current Assets readings, the most recent being $16.3 million for Q4 2023.

  • On a quarterly basis, Current Assets rose 52.54% to $16.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $16.3 million, a 52.54% increase, with the full-year FY2023 number at $16.3 million, up 52.54% from a year prior.
  • Current Assets hit $16.3 million in Q4 2023 for Elicio Therapeutics, down from $19.9 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $133.5 million in Q1 2021 to a low of $10.7 million in Q4 2022.
  • Median Current Assets over the past 4 years was $56.7 million (2022), compared with a mean of $61.8 million.
  • Biggest five-year swings in Current Assets: soared 115.73% in 2021 and later plummeted 88.25% in 2022.
  • Elicio Therapeutics' Current Assets stood at $42.3 million in 2020, then skyrocketed by 115.73% to $91.2 million in 2021, then plummeted by 88.25% to $10.7 million in 2022, then skyrocketed by 52.54% to $16.3 million in 2023.
  • The last three reported values for Current Assets were $16.3 million (Q4 2023), $19.9 million (Q3 2023), and $26.2 million (Q2 2023) per Business Quant data.